# US 2024/0252551 A1 · Novel pluripotent cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252551 A1
- Document ID: US20240252551A1
- Status: Published application
- Kind: A1
- Application number: 18/566,001
- Filed: 2022-06-02
- Published: 2024-08-01
- Earliest claimed: 2021-06-02
- Assignees: Korea Research Institute of Bioscience and Biotechnology; Daegu Gyeongbuk Institute of Science and Technology
- Applicants: Korea Research Institute of Bioscience and Biotechnology; Daegu Gyeongbuk Institute of Science and Technology
- Inventors: Janghwan KIM; Jeongmin HA; Jong Kyoung KIM; Jeong Soo LEE; Mi-Young SON; Kyung-Sook CHUNG; Juhyeon NAM; Areum BAEK; Young Joo JEON
- Web page: https://patentgrep.com/patent/US20240252551A1

## CPC

- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C07K 14/4702: {Regulators; Modulating activity}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- G01N 33/5073: {Stem cells}
- C12N 15/85: for animal cells
- C12N 2501/40: Regulators of development
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2506/02: from embryonic cells
- C12N 2506/1307: from adult fibroblasts
- C12N 2510/00: Genetically modified cells
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to: a method for converting non-pluripotent cells into pluripotent cells; cells produced by the method; and uses thereof. The pluripotent cells of the present invention have low tumorigenicity while having excellent cell differentiation ability and pluripotency capable of differentiating into three germ layers, and can specifically separate pluripotent cells in the intermediate stage of reprogramming, and thus, it is possible to produce pluripotent cells having characteristics different from conventional induced pluripotent stem cells.

## Claims

### Claim 1

A method for converting non-pluripotent cells into pluripotent cells, the method comprising:
inducing the non-pluripotent cells to express reprogramming factors, thereby overexpressing desmosome-related genes or epithelial cell differentiation-related genes.

### Claim 2 (depends on 1)

The method of claim 1, further comprising overexpressing and then reducing the desmosome-related genes or epithelial cell differentiation-related genes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reprogramming factor is one or more factors selected from the group consisting of Oct4, Sox2, Klf4, and c-Myc.

### Claim 4 (depends on 1)

The method of claim 1, comprising restricting the expression of the reprogramming factor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the desmosome-related gene or epithelial cell differentiation-related gene is at least one gene selected from among Dsg3, Dsg4, Dsp, Evp1, Jup, Perp, and Pkp1.

### Claim 6 (depends on 1)

Pluripotent cells produced by the method for converting non-pluripotent cells into pluripotent cells of claim 1.

### Claim 7 (depends on 6)

The pluripotent cells of claim 6, wherein the pluripotent cells exhibit reduced expression of at least one gene selected from the group consisting of Nanog, Rex1, and Esrrb compared to the corresponding genes in induced pluripotent stem cells (iPSCs).

### Claim 8 (depends on 6)

The pluripotent cells of claim 6, wherein the pluripotent cells are possible to differentiate into cells constituting ectoderm, mesoderm, or endoderm.

### Claim 9 (depends on 6)

The pluripotent cells of claim 6, wherein the pluripotent cells have reduced tumorigenicity compared to the iPSCs.

### Claim 10 (depends on 7)

The pluripotent cells of claim 7, wherein the at least one gene exhibits reduced expression by at least 10 times compared to the corresponding gene in the iPSCs.

### Claim 11 (depends on 6)

The pluripotent cells of claim 6, wherein the pluripotent cells have increased expression of Spink2 by at least 10 times compared to the iPSCs.

### Claim 12 (depends on 6)

The pluripotent cells of claim 6, wherein the pluripotent cells further express at least one marker gene selected from the group consisting of Shisa3, Foxo4, Ptp4a3, Blvra, Mbnl3, Mthfd2, and Dctpp1.

### Claim 13

Cells wherein:
the expression of a desmosome-related gene or epithelial cell differentiation-related gene is higher than the expression level of the corresponding gene in iPSCs; or the expression level of Spink2 gene is higher than the expression level of the gene in the iPSCs; and
the expression level of at least one gene selected from the group consisting of Nanog, Rex1, and Esrrb is reduced compared to the expression level of the corresponding gene in the iPSCs.

### Claim 14 (depends on 13)

The cells of claim 13, wherein the cells, in which the expression of desmosome-related genes or epithelial cell differentiation-related genes is higher than the expression level of the corresponding gene in the iPSCs, express Dsp gene and Shisa8 gene.

### Claim 15 (depends on 13)

The cells of claim 13, wherein the cells, in which the expression level of Spink2 gene is higher than the expression level of the gene in the iPSCs, exhibit pluripotency that is the potential to differentiate into any one of ectodermal cells, mesodermal cells, or endodermal cells.

### Claim 16 (depends on 6)

A method for producing cells, the method comprising inducing the differentiation of the pluripotent cells of claim 6.

### Claim 17 (depends on 6, 13)

A composition for cell transplantation or biological tissue regeneration, the composition comprising, as active ingredients:
the pluripotent cells of claim 6;
the cells of claim 13; or the cells produced by the method for producing cells comprising inducing the differentiation of the pluripotent cells of claim 6.

### Claim 18 (depends on 6, 13)

A method for evaluating the efficacy or toxicity of a substance to be tested, the method comprising bringing:
the pluripotent cells of claim 6;
the cells of claim 13; or the cells produced by the method for producing cells comprising inducing the differentiation of the pluripotent cells of claim 6, into contact with the substance to be tested.

### Claim 19 (depends on 6, 13)

A method for regenerating biological tissue by administering to an individual:
the pluripotent cells of claim 6;
the cells of claim 13; or
the cells produced by the method for producing cells comprising inducing the differentiation of the pluripotent cells of claim 6.

### Claim 20 (depends on 6, 13)

A method for treating a transplant patient comprising:
preparing a pharmaceutical composition comprising:
the pluripotent cells of claim 6,
the cells of claim 13, or
differentiated cells derived from the pluripotent cells of claim 6; and
administering an amount of the compound to the patient sufficient to achieve a desired therapeutic response in the patient.

### Claim 21 (depends on 6, 13)

A pharmaceutical composition comprising:
the pluripotent cells of claim 6,
the cells of claim 13, or
a plurality of differentiated cells derived from the pluripotent cells of claim 6; and
an excipient.
